Zeitgemäße Diagnostik und Therapie der Osteoporose

 

 Buy Article Permissions and Reprints

Zusammenfassung

Im Rahmen der von der Weltgesundheitsorganisation ausgerufenen „Bone and Joint Decade 2000-2010“ wird den Erkrankungen und Verletzungen des Bewegungsapparats zunehmend mehr Aufmerksamkeit gewidmet. Vor allem die Osteoporose ist im Hinblick auf eine immer älter werdende Gesellschaft von großer medizinischer und volkswirtschaftlicher Bedeutung. Die Fraktur stellt im Verlauf der Osteoporose das entscheidende Ereignis dar. Für den einzelnen Patienten ist sie die größte Einschränkung seiner Lebensqualität und sozialökonomisch der Hauptkostenfaktor. Dem Chirurgen und Unfallchirurgen kommt hierbei die entscheidende Schlüsselrolle zu. Leitet er nach einer stattgehabten Fraktur die Diagnostik und ggf. Therapie ein, so lässt sich die Anzahl der sonst so häufigen Folgefrakturen deutlich reduzieren. Die Durchführung der effektiven Primärdiagnostik und Therapie ist anhand nationaler und internationaler Leitlinien schnell und einfach durchführbar.

Abstract

Since the World Health Organisation's announcement of the “Bone and Joint Decade 2000-2010” diseases of the musculoskeletal system attract more and more attention throughout patients and professional health care providers. In an aging society especially osteoporosis represents a major public health concern. Fragility fractures are the most limiting condition in osteoporosis with the highest impact on both, life quality and health care systems worldwide. Orthopaedic surgeons play a key role in implementing primary diagnostics and therapy in patients with fragility fractures. Objective of this effort is the reduction of the common subsequent fractures in patients with osteoporosis. According to national and international guidelines implementation of contemporary clinical pathways to diagnose and treat patients with fractures due to diminished bone mineral density is fast, simple and proven to be effective.

Literatur

• 1 Bartl R. Osteoporose - Prävention, Diagnostik, Therapie. Thieme, Stuttgart New York 2001
  Google Scholar
• 2 Bartl R, Bartl C, Mutschler W. Diagnostik und Therapie der Osteoporose.  Unfallchirurg. 2003;  106 526-541
  CrossrefPubMedGoogle Scholar
• 3 Black DM, Thompson DE, Bauer D. et al . Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial.  Osteoporos Int. 2000;  85 4118-4124
  CrossrefPubMedGoogle Scholar
• 4 Black DM, Nevitt MC, Palermo L. Prediction of new vertebral deformities.  J Bone Miner Res. 1994;  9 ((suppl)) 135
  PubMedGoogle Scholar
• 5 Black DM, Cummings SR, Karpf DB. et al . Randomised trial of effect of alendronate on rik of fracture in women with existing vertebral fractures.  The Lancet. 1996;  348 1535-1541
  CrossrefPubMedGoogle Scholar
• 6 .  http://www.boneandjointdecade.org/
  Google Scholar
• 7 Cuddihy MT, Gabriel SE, Crowson CS. et al . Osteoporosis intervention following distal forearm fractures : a missed opportunity?.  Arch Intern Med. 2002;  162 421-426
  CrossrefPubMedGoogle Scholar
• 8 Cummings SR, Nevitt MC, Browner WS. Risc factors for hip fracture in white women.  N Eng J Med. 1995;  332 767-773
  CrossrefPubMedGoogle Scholar
• 9 Dawson-Huges B, Harris SS, Krall EA. et al . Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older.  N Eng J Med. 1997;  337 670-676
  PubMedGoogle Scholar
• 10 Delmas PD. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.  Osteoporos Int. 2005;  16 ((Suppl 1)) 16-19
  CrossrefPubMedGoogle Scholar
• 11 Freedman KB, Kaplan FS, Bilker WB. et al . Treatment of Osteoporosis: Are Physicians Missing an Opportunity?.  JBJS. 2000;  82-A 1063-1070
  PubMedGoogle Scholar
• 12 Götte S, Dittmar K. Epidemiologie und Kosten der Osteoporose.  Orthopäde. 2001;  30 402-404
  CrossrefPubMedGoogle Scholar
• 13 Hanley DA, Josse RG. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada.  CMAJ. 1996;  155 921-923
  PubMedGoogle Scholar
• 14 Johnell O, Kanis JA, Oden A. et al . Fractrure risc following an osteoporotc fracture.  Osteoporos Int. 2004;  15 175-179
  CrossrefPubMedGoogle Scholar
• 15 Jones G, Nguyen T, Sambrook PN. et al . Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES).  Osteoporos Int. 1994;  4 277-282
  CrossrefPubMedGoogle Scholar
• 16 Kuehn BM. Longer-lasting osteoporosis drugs sought.  JAMA. 2005;  293 2458
  CrossrefPubMedGoogle Scholar
• 17 Lips P. Vitamin D deficiency and secondary hyperparathyreoidism in the elderly: consequences for bone loss and fractures and therapeutic implications.  Endocrine Reviews. 2001;  22 477-501
  CrossrefPubMedGoogle Scholar
• 18 Neer R, Arnaud C, Zanchetta J. et al . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal wommen with osteoporosis.  N Engl J Med. 2001;  344 1434-1441
  CrossrefPubMedGoogle Scholar
• 19 ÓGradaigh D, Debiram I, Love S. et al . A prospective study of discordance in diagnosis of osteoporosis using spine and proximal femur bone densitometry.  Osteoporos Int. 2003;  14 13-18
  CrossrefPubMedGoogle Scholar
• 20 Reginster JY, Minne HW, Sorensen OH. et al . Randomized Trial of the Effect of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis.  Osteoporos Int. 200;  11 83-91
  PubMedGoogle Scholar
• 21 Report of a WHO Scientific Group . Prevention and Management of Osteoporosis.  WHO Technical Report Series. 2003;  , No 921
  PubMedGoogle Scholar
• 22 Ross PD. Osteoporosis: frequency, consequences, and risk factors.  Arch Intern Med. 1996;  156 1399-1411
  CrossrefPubMedGoogle Scholar
• 23 Sim MF, Stone MD, Phillips CJ. et al . Cost effectiveness analysis of using quantitative ultrasound as a selective pre-screen for bone densitometry.  Technol Health Care. 2005;  13 75-85
  PubMedGoogle Scholar
• 24 Siris E, Adachi JD, Lu Y. et al . Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.  Osteoporos Int. 2002;  13 907-913
  CrossrefPubMedGoogle Scholar
• 25 Smith MD, Ross W, Ahern MJ. Missing a therapeutic window of opportunity: an audit of patients attending a tertiary teaching hospital with potentially osteoporotic hip an wrist fractures.  J Rheumatol. 2001;  28 2504-2508
  PubMedGoogle Scholar
• 26 Vogel T, Dobler T, Bitterling H. et al . Osteoporose in der Unfallchirurgie: Prävalenz und Management.  Unfallchirurg. 2005;  108 356-364
  CrossrefPubMedGoogle Scholar
• 27 World Health Organization . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.  Technical Report Series. WHO. 1994;  , Genf.
  PubMedGoogle Scholar

Korrespondenzadresse

Tobias Vogel

Klinikum der Universität München-Innenstadt·Ludwig-Maximilians-Universität

Nussbaumstraße 20

80336 München

Phone: +49/89/51 60 25 88

Fax: +49/89/51 60 49 58

Email: tobias.vogel@med.uni-muenchen.de